In vivo expression of cyclooxygenase-1 in activated microglia and macrophages during neuroinflammation visualized by PET with 11C- ketoprofen methyl ester

Journal of Nuclear Medicine

Volumn 52, Issue 7, 2011, Pages 1094-1101

  Shukuri, Miho ^a,b   Takashima Hirano, Misato ^a   Tokuda, Keiko ^a   Takashima, Tadayuki ^a   Matsumura, Kiyoshi ^c   Inoue, Osamu ^b   Doi, Hisashi ^a   Suzuki, Masaaki ^a   Watanabe, Yasuyoshi ^a   Onoe, Hirotaka ^a  

^a RIKEN   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c OSAKA INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Arachidonic acid cascade; Innate immunity; Molecular imaging; NSAIDs; PET

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; KETOPROFEN METHYL ESTER CARBON 11; LIPOPOLYSACCHARIDE; QUINOLINIC ACID; RADIOISOTOPE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CELL ACTIVATION; CELL POPULATION; CELL SPECIFICITY; CELL TYPE; CONTROLLED STUDY; EX VIVO STUDY; EXPERIMENTAL MODEL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MACROPHAGE ACTIVATION; MALE; MICROGLIA ACTIVATION; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; BRAIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GENE EXPRESSION REGULATION, ENZYMOLOGIC; INFLAMMATION; KETOPROFEN; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MICE; MICROGLIA; NEUROTOXINS; POSITRON-EMISSION TOMOGRAPHY; QUINOLINIC ACID; RATS; TIME FACTORS;

EID: 79960336672     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.084046     Document Type: Article

References (40)

1. Cartier L, Hartley O, Dubois-Dauphin M, Krause KH. Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases. Brain Res Brain Res Rev. 2005;48:16-42. (Pubitemid 40215781)
2. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140:918-934.
3. Phillis JW, Horrocks LA, Farooqui AA. Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. Brain Res Rev. 2006;52:201-243. (Pubitemid 44291802)
4. Farooqui AA, Horrocks LA, Farooqui T. Modulation of inflammation in brain: a matter of fat. J Neurochem. 2007;101:577-599. (Pubitemid 46633316)
5. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem. 1996;271:33157-33160. (Pubitemid 27010118)
6. Bazan NG, Fletcher BS, Herschman HR, Mukherjee PK. Platelet-activating factor and retinoic acid synergistically activate the inducible prostaglandin synthase gene. Proc Natl Acad Sci USA. 1994;91:5252-5256. (Pubitemid 24174304)
7. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol. 2004;63:901-910. (Pubitemid 39202493)
8. Choi SH, Aid S, Bosetti F. The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research. Trends Pharmacol Sci. 2009;30:174-181.
9. Schwab JM, Nguyen TD, Postler E, Meyermann R, Schluesener HJ. Selective accumulation of cyclooxygenase-1-expressing microglial cells/macrophages in lesions of human focal cerebral ischemia. Acta Neuropathol. 2000;99:609-614. (Pubitemid 30307369)
10. Schwab JM, Beschorner R, Meyermann R, Gözalan F, Schluesener HJ. Persistent accumulation of cyclooxygenase-1-expressing microglial cells and macrophages and transient upregulation by endothelium in human brain injury. J Neurosurg. 2002;96:892-899. (Pubitemid 34415404)
11. Hoozemans JJ, Rozemuller JM, van Haastert ES, Veerhuis R, Eikelenboom P. Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology. Curr Pharm Des. 2008;14:1419-1427. (Pubitemid 351982549)
12. de Vries EF. Imaging of cyclooxygenase-2 (COX-2) expression: potential use in diagnosis and drug evaluation. Curr Pharm Des. 2006;12:3847-3856. (Pubitemid 44560698)
13. 18F-desbromo-DuP-697 as a PET tracer for cyclooxygenase-2 expression. J Nucl Med. 2003;44:1700-1706.
14. Gao M, Wang M, Miller KD, Hutchins GD, Zheng QH. Synthesis of carbon-11 labeled celecoxib derivatives as new candidate PET radioligands for imaging of inflammation. Appl Radiat Isot. 2009;67:2019-2024.
15. 11C-labeling of 2-arylpropionic acids and their esters: construction of a PET tracer library for a study of biological events involved in COXs expression. Chemistry. 2010;16:4250-4258.
16. Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B, Hong JS. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci. 2000;20:6309-6316. (Pubitemid 30658427)
17. Rivest S. Molecular insights on the cerebral innate immune system. Brain Behav Immun. 2003;17:13-19. (Pubitemid 36207597)
18. Duan WM, Widner H, Cameron RM, Brundin P. Quinolinic acid-induced inflammation in the striatum does not impair the survival of neural allografts in the rat. Eur J Neurosci. 1998;10:2595-2606. (Pubitemid 28362567)
19. Schwarcz R, Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther. 2002;303: 1-10.
20. 11C]PK 11195 and comparison of their behaviours as radioligands for PK binding sites in rats. Nucl Med Biol. 1994;21:573-581.
21. Guide for the Care and Use of Laboratory Animals. Washington, DC: Government Printing Office; 1985. NIH publication 86-23.
22. Langenbach R, Morham SG, Tiano HF, et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell. 1995;83:483-492.
23. Morham SG, Langenbach R, Loftin CD, et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell. 1995;83: 473-482.
24. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. 6th ed. Burlington, MA: Academic Press; 2007.
25. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA. 1999;96:7563-7568. (Pubitemid 29299702)
26. Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA. 2002;99:13926-13931. (Pubitemid 35215482)
27. Thomas DM, Kuhn DM. Cyclooxygenase-2 is an obligatory factor in methamphetamine-induced neurotoxicity. J Pharmacol Exp Ther. 2005;313:870-876. (Pubitemid 40604190)
28. Shankaran M, Marino ME, Busch R, et al. Measurement of brain microglial proliferation rates in vivo in response to neuroinflammatory stimuli: application to drug discovery. J Neurosci Res. 2007;85:2374-2384. (Pubitemid 47204752)
29. Zito MA, Koennecke LA, McAuliffe MJ, McNally B, van Rooijen N, Heyes MP. Depletion of systemic macrophages by liposome-encapsulated clodronate attenuates striatal macrophage invasion and neurodegeneration following local endotoxin infusion in gerbils. Brain Res. 2001;892:13-26. (Pubitemid 32126563)
30. Bauer MK, Lieb K, Schulze-Osthoff K, et al. Expression and regulation of cyclooxygenase-2 in rat microglia. Eur J Biochem. 1997;243:726-731. (Pubitemid 27073441)
31. de Meira Santos Lima M, Braga Reksidler A, Marques Zanata S, Bueno Machado H, Tufik S, Vital MA. Different parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats. Brain Res. 2006;1101:117-125. (Pubitemid 44036768)
32. Teismann P, Tieu K, Choi DK, et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA. 2003;100:5473-5478. (Pubitemid 36542729)
33. Choi SH, Langenbach R, Bosetti F. Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharide-induced inflammatory response and brain injury. FASEB J. 2008;22:1491-1501. (Pubitemid 351656789)
34. Aid S, Langenbach R, Bosetti F. Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2. J Neuroinflammation. 2008;5:17-30.
35. Aid S, Silva AC, Candelario-Jalil E, Choi SH, Rosenberg GA, Bosetti F. Cyclooxygenase-1 and -2 differentially modulate lipopolysaccharide-induced bloodbrain barrier disruption through matrix metalloproteinase activity. J Cereb Blood Flow Metab. 2010;30:370-380.
36. Salzberg-Brenhouse HC, Chen EY, Emerich DF, et al. Inhibitors of cyclooxygenase-2, but not cyclooxygenase-1 provide structural and functional protection against quinolinic acid-induced neurodegeneration. J Pharmacol Exp Ther. 2003;306:218-228. (Pubitemid 36734376)
37. 11C] PK11195 by PET and induction of the peripheral-type benzodiazepine receptor after transient focal ischemia in rats. J Cereb Blood Flow Metab. 2007;27:1975-1986.
38. Venneti S, Lopresti BJ, Wang G, et al. A comparison of the high-affinity peripheral benzodiazepine receptor ligands DAA1106 and (R)-PK11195 in rat models of neuroinflammation: implications for PET imaging of microglial activation. J Neurochem. 2007;102:2118-2131. (Pubitemid 47329281)
39. Venneti S, Lopresti BJ, Wiley CA. The peripheral benzodiazepine receptor (translocator protein 18kDa) in microglia: from pathology to imaging. Prog Neurobiol. 2006;80:308-322.
40. Chen MK, Baidoo K, Verina T, Guilarte TR. Peripheral benzodiazepine receptor imaging in CNS demyelination: functional implications of anatomical and cellular localization. Brain. 2004;127:1379-1392. (Pubitemid 38745516)